Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Marcelo Muino"'
1
Vitiligo is correlated with clinical benefits in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors (ICI)
Autor: Marcelo Muino, Mariana Abal, Carlos Fernando Garcia Gerardi, Liliana D Gonzalez, Felipe G. Gercovich, Marcelo Andres Nunell, Cesar Gonzalez, Flavio Tognelli, Ernesto Gil Deza, Edgardo G. J. Rivarola, Alba Marin Ordoñez, Eduardo L. Morgenfeld, Gaston Martin Reinas
Publikováno v: Journal of Clinical Oncology. 38:e22023-e22023
e22023 Background: Use of ICI changed the treatment of Advanced Cutaneous Melanoma Patients (ACMP). This paper analyzes the evolution of ACMP who develop vitiligo during ICI treatment at Instituto Oncológico Henry Moore (IOHM). Methods: We selected
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::379055bc549c0705f922d1202c6931de
https://doi.org/10.1200/jco.2020.38.15_suppl.e22023
Zobrazit plný text záznamu
2
Real-world evidence: A retrospective-cohort study of castration-resistant advanced prostate cancer (CRAPC) patients treated with abiraterone 1000 mg or 250 mg
Autor: Edgardo G. J. Rivarola, Sandra L. Ares, Felipe G. Gercovich, Claudia Lorena Acuna, Ernesto Gil Deza, Liliana D Gonzalez, Cesar Gonzalez, Carlos Fernando Garcia Gerardi, Leonel Smolje, Dario Niewiadomski, Marcelo Muino, Eduardo L. Morgenfeld
Publikováno v: Journal of Clinical Oncology. 38:e19315-e19315
e19315 Background: The efficacy of Abiraterone 250 mg with food was established ten years ago (Ryan JCO 2010). Recent publications (Szmulewitz JCO 2018) have concluded that 1000 mg on an empty stomach or 250 mg with food have similar results. This pa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8175d7a203ffd0c743bc169ea4a6599a
https://doi.org/10.1200/jco.2020.38.15_suppl.e19315
Zobrazit plný text záznamu
3
Lessons on humanity: The voice of cancer patients through a literary contest
Autor: Lourdes Gil Deza, Marta Dragosky, Dario Niewiadomski, Eduardo L. Morgenfeld, Felipe G. Gercovich, Ernesto Gil Deza, N. Gercovich, Leonel Smolje, Claudia Lorena Acuna, Alba Marin Ordoñez, Edgardo G. J. Rivarola, Inés Danussi, Flavio Tognelli, Marcelo Muino, Daniela Gercovich, Sandra L. Ares
Publikováno v: Journal of Clinical Oncology. 38:e24189-e24189
e24189 Background: Most cancer narratives are provided by skilled American and British writers (Broyard, Hitchens, Jobs, Kalanithi, Pausch, Sacks, Sontag or Wishart). This paper highlights the voice of ordinary Latin American patients who wrote about
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1fc29fc873c1e524be0928d12b7aad4d
https://doi.org/10.1200/jco.2020.38.15_suppl.e24189
Zobrazit plný text záznamu
5
Business versus science: High drug prices conspire against oncological research
Autor: Leonardo Smolje, Marcelo Muino, Felipe G. Gercovich, Mariana Abal, Eduardo L. Morgenfeld, Edgardo G. J. Rivarola, Ernesto Gil Deza, Gaston Martin Reinas, Marvin Albert Mizrahi
Publikováno v: Journal of Clinical Oncology. 37:e14580-e14580
e14580 Background: It has been consistently proven that pivotal clinical trials (PCT) for drug registration or new drug indications (NDI), sponsored by the pharmaceutical industry, obtain better results than independent confirmatory studies (ICS). Th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5efc7b43467b8b0081082abfa90e2f51
https://doi.org/10.1200/jco.2019.37.15_suppl.e14580
Zobrazit plný text záznamu
6
Patient safety: A progressive deprescribing model in patients with advanced solid tumors assisted at Instituto Oncológico Henry Moore (IOHM)
Autor: Mariana Abal, Marcelo Muino, Monica Montiel, Carlos Fernando Garcia Gerardi, Edgardo G. J. Rivarola, Eduardo L. Morgenfeld, Ernesto Gil Deza, Sandra L. Ares, Flavio Tognelli, Felipe G. Gercovich
Publikováno v: Journal of Clinical Oncology. 35:6594-6594
6594 Background: "Deprescribing is the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy and improving outcomes" ( Br J Clin Pharmacol 80:6, 1254. 2015). The aim of t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef348c3972ab9163ce111e90e5143a9f
https://doi.org/10.1200/jco.2017.35.15_suppl.6594
Zobrazit plný text záznamu
7
Phase II Study of Gemcitabine, 5-Fluorouracil, and Leucovorin in Patients With Pancreatic Cancer
Autor: Francisco Lastiri, Marcelo Muino, José Luis Castilla, S. Jovtis, Luis Balbiani, Mariana Abal, Roberto Pinckevicius, Adolfo Marantz, D. Lewi, Silvia Agusto, Eduardo Almira, Graciela Pasccon, Graciela Uranga, Luis Fein, Mónica Reale
Publikováno v: Seminars in Oncology. 28:44-49
The primary goal of this phase II study was to determine the efficacy of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus 5-fluorouracil in patients with pancreatic cancer. Eligibility criteria included nonresectable locally advance
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::afdd06435c283d0bba23ac99a62798be
https://doi.org/10.1016/s0093-7754(01)80008-7
Zobrazit plný text záznamu
8
Rate of second malignant neoplasm in a cohort of early stage uveal melanoma followed at Instituto Oncológico Henry Moore (IOHM) in the last 15 years
Autor: Edgardo G. J. Rivarola, Ernesto Gil Deza, Flavio Tognelli, Marcelo Muino, Felipe G. Gercovich, Eduardo L. Morgenfeld, Gaston Martin Reinas
Publikováno v: Journal of Clinical Oncology. 34:9587-9587
9587Background: Uveal melanoma (UM) is a rare neoplasm with a 3.3% rate of second malignant neoplasm (SMN) according to the Collaborative Ocular Melanoma Study (COMS) (Diener-West m et al. Arch Oph...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9fd94e26bb81a49437deba8c0d2d16f
https://doi.org/10.1200/jco.2016.34.15_suppl.9587
Zobrazit plný text záznamu
9
Discrepancies between immunohistochemistry (IHC) form core biopsy (CB) and surgical specimen (SP) in patients with early breast cancer (EBC): A clinical decision-making challenge
Autor: Sandra L. Ares, N. Gercovich, Marcelo Muino, Edgardo G. J. Rivarola, Gabriela Malcervelli, Eduardo L. Morgenfeld, Silvina Laura Musini, Ernesto Gil Deza, Felipe G. Gercovich
Publikováno v: Journal of Clinical Oncology. 34:e12072-e12072
e12072Background: Various studies analyze the differences found between the IHC from CB and the SP. The discordance in this information can bring serious problems when it comes to making clinical decisions. Methods: In this retrospective study, we ev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f35e88c5ec53f2bf095cf13505f5f12f
https://doi.org/10.1200/jco.2016.34.15_suppl.e12072
Zobrazit plný text záznamu
10
Off-label prescriptions in cancer: Who should pay for them?
Autor: D. Juarez, C. Garcia Gerardi, S. Aguirre, M. L. Fischer, Sandra L. Ares, Monica Montiel, Eduardo L. Morgenfeld, M. Abal, Felipe G. Gercovich, Mario Javier Nacul, Edgardo G. J. Rivarola, E. Gil Deza, A. Negro, Marcelo Muino, F. Negro
Publikováno v: Journal of Clinical Oncology. 29:e16559-e16559
e16559 Background: At the 2007 ASCO meeting we presented the results of the first 26 months of our team’s work in a paper entitled: Standard therapy deviations in the practice of clinical oncology ...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f8cae729a121b22c944085a9359409b
https://doi.org/10.1200/jco.2011.29.15_suppl.e16559
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje